Given the common occurrence of NF1 mutation in BRAF-WT melanoma, which renders patients unsuitable for BRAF targeting, it is crucial to thoroughly understand NF1-mutated melanoma to guide the development of appropriate treatments for this aggressive subtype. This evidence concerns the gene NF1 and melanoma.